Online courses address various topics including distress screening and management, survivorship, palliative care, pain management, communicating prognosis to patients, and hospice referral.
A series of training courses on supportive oncology care developed by the Coleman Supportive Oncology Collaborative (CSOC) is now available online through the National Comprehensive Cancer Network (NCCN). The courses are based on guidelines and standards from the NCCN, the American Society of Clinical Oncology, the Commission on Cancer, and the National Academy of Medicine. The courses are free, offer credits for nurses’ continuing education and AMA PRA Category 1 Credits™. Aimed at helping physicians, nurses, and other health professionals learn more about supportive care for cancer patients, they address various topics including distress screening and management, survivorship, palliative care, pain management, communicating prognosis to patients, and hospice referral.
Anyone involved with cancer care can benefit from these courses,” said Christine Weldon, M.B.A., Director of the Center for Business Models in Healthcare, who helped facilitate the creation CSOC and the development of the courses. “Many social workers and psychologists have taken them.”
Rising out of the larger efforts of the CSOC to evaluate and improve supportive care, the courses are intended to encourage a more consistent understanding and vocabulary for staff and professionals at cancer centers to use to talk about some of the challenges faced by patients.
The courses are intentionally short — 7 to 15 minutes each — and are intended to be introductory. Each course comes with a downloadable PDF that contains information on other available training resources on those topics.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.